The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
posted on 2025-08-06, 14:07authored bySusan Ball, J Vickery, J Hobart, D Wright, C Green, J Shearer, A Nunn, M Gomez Cano, D MacManus, D Miller, S Mallik, J Zajicek
The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial aimed to determine whether or not oral Δ(9)-tetrahydrocannabinol (Δ(9)-THC) slowed the course of progressive multiple sclerosis (MS); evaluate safety of cannabinoid administration; and, improve methods for testing treatments in progressive MS.
Funding
Medical Research Council Efficacy and Mechanism Evaluation programme
Multiple Sclerosis Society
Multiple Sclerosis Trust
The National Institute for Health Research Health Technology Assessment programme